Samantha Semenkow

Stock Analyst at Citigroup

(0)
# 5013
Out of 5,386 analysts
52
Total ratings
Success rate
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
PRME Prime Medicine
Downgrades: Neutral
10 2
2.42 -38.02% 3 May 27, 2025
CABA Cabaletta Bio
Maintains: Buy
17 13
1.58 722.78% 3 May 16, 2025
ALLO Allogene Therapeutic...
Maintains: Buy
8 4
1.18 238.98% 3 May 15, 2025
ARGX argenx
Maintains: Strong Buy
796 803
559.65 43.48% 6 May 9, 2025
GPCR Structure Therapeuti...
Initiates Coverage On: Buy
60
21.11 184.23% 1 May 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 5
4.2 19.05% 3 Mar 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
6 3
n/a n/a 2 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
12
2.96 305.41% 1 Dec 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
27 31
21.78 42.33% 2 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
8 15
2.83 430.04% 2 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Buy
80
8.53 837.87% 2 Jun 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
10 14
3.02 363.58% 6 May 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
16 15
2.27 560.79% 4 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
9 12
n/a n/a 2 Apr 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
47.34 52.09% 1 Dec 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
46
n/a n/a 1 Dec 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
33 50
16.12 210.17% 3 Sep 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 56
16.8 233.33% 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
2 1
n/a n/a 3 May 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
n/a n/a 1 May 3, 2023